Healthcare costs, particularly pharmaceutical costs, are a dominant issue for most healthcare organizations, but it is unclear if randomized controlled trials (RCTs) routinely discuss costs. Our objective was to assess the frequency and factors associated with the inclusion of costs in RCTs.
Methods and Findings
We randomly sampled 188 RCTs spanning three years (2003-2005) from six high impact journals. The sample size for RCTs was based on a calculation to estimate the inclusion of actual drug costs with a precision of +/−3%. Two reviewers independently extracted cost data and study characteristics. Frequencies were calculated and potential characteristics associated with the inclusion of costs were explored. Actual drug costs were included in 4.7% (9/188) of RCTs; any actual costs were included in 7.4% (14/188) of RCTs; and any mention of costs was included in 27.7% (52/188) of RCTs. As the amount of industry funding increased across RCTs, from non-profit to mixed to fully industry funded RCTs, there was a statistically significant reduction in the number of RCTs with any actual costs (Cochran-Armitage test, p = 0.005) and any mention of costs (Cochran-Armitage test, p = 0.02). Logistic regression analysis also indicated funding was associated with the inclusion of any actual cost (OR = 0.34, p = 0.009) or any mention of costs (OR = 0.63, p = 0.02). Journal, study conclusions, study location, primary author's country and product age were not associated with inclusion of cost information.
While physicians are encouraged to consider costs when prescribing drugs for their patients, actual drug costs were provided in only 5% of RCTs and were not mentioned at all in 72% of RCTs. Industry funded trials were less likely to include cost information. No other factors were associated with the inclusion of cost information.
Citation: Allan GM, Korownyk C, LaSalle K, Vandermeer B, Ma V, et al. (2010) Do Randomized Controlled Trials Discuss Healthcare Costs? PLoS ONE 5(8): e12318. doi:10.1371/journal.pone.0012318
Editor: Joseph S. Ross, Yale University School of Medicine, United States of America
Received: June 7, 2010; Accepted: July 28, 2010; Published: August 23, 2010
Copyright: © 2010 Allan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The project was funded by a $10,000 grant from the Institute of Health Economics. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
The costs of pharmaceuticals in almost all countries of the Organisation for Economic Co-operation and Development (OECD) are increasing faster than any other aspect of healthcare budgets . Many countries struggle with a wide variety of strategies to reduce or control pharmaceutical spending , , but many approaches increase drug costs for patients, often worsen outcomes and shift costs to other areas –. Surveys have found that physicians consider health care costs to be important when prescribing, even when patients have full drug coverage –. Other studies have observed that physicians' prescribing was responsive to price when costs were made available to them –. A number of studies in the clinical setting have found that prescribing costs declined without negative impacts on care if physicians were given feedback about their prescribing costs and provided with cost information –. Ideally, physicians would select less expensive products if the alternatives were equally efficacious. Unfortunately, physicians have a very limited understanding of drug cost and, more importantly, do not understand the large cost differential between expensive and inexpensive drugs .
Physicians have indicated they want more cost information , although several researchers have reported that cost information was difficult to obtain , . Currently, there are no data quantifying the availability of this information in the medical literature.
Our objective was to determine how often actual drug costs and healthcare costs in general were included in randomized controlled trials (RCTs) and to identify the factors that may be associated with the inclusion of cost information in RCTs.
Although there are no established templates for studies assessing reporting in the literature, PRISMA , the guide for reporting of systematic reviews, serves as a reasonable model and was followed where possible.
Our study was limited to RCTs, the gold-standard of therapy evidence. To address the inclusion of drug costs, only RCTs comparing a pharmaceutical to no treatment, placebo or active control were eligible.
Similar to past studies that assessed reporting in the literature , , we used six major general medical journals to sample RCTs: New England Journal of Medicine (N Eng J Med), Journal of the American Medical Association (JAMA), Lancet, British Medical Journal (BMJ), Annals of Internal Medicine (Ann Intern Med) and Archives of Internal Medicine (Arch Intern Med).
We used PubMed to identify all RCTs. A search was performed in May 2006 using the abbreviated journal title restricted to the date range January 1 to December 31 for each individual year (2003, 2004 or 2005) and Randomized Controlled Trial for type of article. For example, to search for RCTs published in the N Engl J Med in 2005, we entered N Engl J Med in the search bar and limited the search to RCTs under type of article and the dates to January 1, 2005 to December 31, 2005. To confirm these searches captured all the RCTs published in journals, we reviewed each issue from two of journals for 2005 and found none were missed. The PubMed search did capture a few articles that were not RCTs but these were identified during review for inclusion.
The total number of articles found in each search of article type, journal and year (e.g., RCTs in N Engl J Med in 2005) was used to generate the randomization for that group. Randomization was performed using Excel.
The sample size was based on our objective to obtain an accurate and precise estimate of reporting of actual drug costs in RCTs. Initially, 10 articles were randomly selected from each of the six journals published in the year 2005. An interim analysis of those 60 RCTs found that actual drug costs were reported in less than 5% of the RCTs. To attain a precision of +/− 3% with a 95% Confidence Interval (CI), 188 RCTs had to be reviewed, assuming the reporting of actual cost was ≤5%. In addition to 10 RCTs from 2005 from each journal, 10 RCTs were randomly selected from each journal for the years 2003 and 2004. Eight more studies were randomly selected from any of the included years or journals.
The abstract of each article randomly selected was reviewed to confirm it met the eligibility criteria: an RCT that assessed pharmaceutical therapy. If it did not, a random number was again generated to choose a replacement RCT.
To identify cost information, two authors (GMA & KL) independently searched each RCT with the Adobe Reader Search function using the key words “cost”, “pric”, “$”, “dollar”, “pound”, “£”, “money”, “fee”, “fund”, “econom”, “financ”, and “expens”. One author (KL) also read each RCT for any mention or discussion of costs. We classified costs in to three categories: actual drug costs, any actual costs, and any mention of costs. ‘Actual drug costs’ were any specific drug cost provided as a numeric value in dollars, pounds or other currency. ‘Any actual costs’ were any drug cost and/or any healthcare cost provided as a numeric value in dollars, pounds or other currency. ‘Any mention of costs’ was considered any of the above plus any discussion of health care costs, no matter how general (e.g. the management of this condition is very expensive). We limited counting ‘any mention of costs’ to once per paragraph when costs were discussed without numeric values. This was because a single paragraph may have frequently included words such as “cost”, “expense”, or “economic”, but the rest of the article had no other discussion of costs. We did not count costs relating to expenses of the trial (e.g. “we paid participants $5 to complete the testing”), funding sources or financial conflict of interest. Finally, we did not count costs-associated words appearing in reference sections.
Two authors (GMA and CK) independently abstracted data on RCT characteristics: experimental drug, age of the experimental drug (novel or established), the comparator, funding of the trial, study country, primary author's country and conclusion. We defined the age of the experimental drug as “novel” if it was still on-patent at the time of the study and as “established” if it was off-patent at the time of the study. Funding was divided into categories of industry, non-profit or mixed. Funding was classified as mixed if the study had both non-profit and industry funding sources. If a study had any industry funding, even if only supplying the pharmaceutical product, it was classified as mixed. We found that classifying conclusions as simply “positive” or “negative” did not reflect the range of language used by authors to explain their results. Therefore, we modified the classification used by Kjaergard and Als-Nielsen  by shortening their ranking of 6 into 4 (combining the ranks of 5 & 4 and 2 & 3). Our four options were: Positive, Positive But, Negative But and Negative. Any disagreements were resolved with discussion and consensus. The data abstraction template is available in Appendix S1. In extracting cost information, we originally had more sub-categories but found the frequency of cost reporting so infrequent it did not warrant multiple sub-categories.
Similar to previous studies ,  that assessed reporting in the literature, we compared the data extraction from a sample of the RCTs to determine inter-rater agreement. We used the abstraction data from two journals (63 RCTs) to compare general agreement over cost and RCT characteristics. We also assessed the Kappa values for areas with a higher potential for disagreement: the age of the experimental drug (novel or established), funding of the trial and conclusion.
We summarized the results to provide a descriptive analysis including overall mean percent of studies which had actual drug costs, any actual costs and any mention of costs, with 95% CI. We originally intended to compare the inclusion of actual drug costs or any mention of costs across different study characteristics (e.g., funding or product age). However, RCTs with actual drug costs were so few in number that we opted to analyze any actual costs (actual drug costs or any other healthcare cost with numeric value in a dollars, pounds or any currency) and any mention of cost. We used Fisher-Freeman-Halton test for nominal data to compare the number of RCTs that included actual costs and any mention of costs associated with different journals, primary author's country or study location. We used Cochran-Armitage test for ordinal data to compare the number of RCTs that included actual costs and any mention of costs associated with funding and study conclusions. We used Fisher's Exact Test to compare the number of RCTs that included actual costs and any mention of costs associated with product age (novel or established). We also did a logistic regression to compare the dependant variables of actual cost and mention of cost simultaneously with the independent variables of funding, conclusion, primary author's country, and product age.
A total of 188 RCTs were reviewed (a full list is available in Appendix S2). Disagreement between reviewers was uncommon. From a sample of 63 RCTs (from two journals), agreement in extracting cost information was 94% and agreement in extraction for RCT variables (such as funding, outcomes, etc) was 91%. The Kappa values for the age of the experimental drug (novel or established) was 0.87, funding of the trial 0.74, and the conclusion 0.75. All disagreements were resolved with discussion.
Table 1 reports how often costs were mentioned in RCTs. The number of RCTs with actual drug costs in dollars, pounds or other currency was 9 of 188 or 4.7% (95% CI, 1.7%–7.7%). The number of RCTs with any actual cost (of drugs and/or other healthcare in dollars, pounds or other currencies) was 14 of 188 or 7.4% (95% CI, 3.7%–11.1%), varying among the journals from 3% (1/32) to 19% (6/32) although the difference was not statistically significant (Fisher-Freeman-Halton test, p = 0.17). The number of RCTs with any mention of costs was 52 of 188 or 27.7% (95% CI, 20.6%–33.3%), varying among the journals from 23% (7/31) to 31% (10/32), although the difference was not statistically significant (Fisher-Freeman-Halton test, p = 0.97).
Table 1. Inclusion of drug costs, health care cost or any mention of cost in Randomized Controlled Trials.doi:10.1371/journal.pone.0012318.t001
Costs were mentioned 166 times in the RCTs for a mean of 0.9 mentions per RCT. However, the median number of times that cost was mentioned was 0 because 72% of RCTs did not include any costs. Of the RCTs with any mention of costs (52 of 188), there was an average of 3.2 mentions per RCT and a median of 1.5 mentions per RCT. Half (26 of 52) of the RCTs including costs only mentioned them once. Six of the 188 RCTs had 10 or more (maximum 21) mentions of costs per article and account for 90 of the 166 mentions overall. Therefore, 3% of the articles account for 54% of the total number of times that costs were mentioned.
Table 2 provides the frequency of costs mentioned in RCTs grouped by study characteristics. Comparing RCTs based on funding, there was a statistically significant reduction in the number of RCTs including any actual costs (Cochran-Armitage test, p = 0.005) and any mention of costs (Cochran-Armitage test, p = 0.02) from non-profit to mixed to industry funded studies. Compared to RCTs of novel drugs, RCTs of established drugs were significantly more likely to include any actual costs (fisher's exact test, p = 0.02), although were not more likely to include any mention of costs (fisher's exact test, p = 0.51).
Table 2. Study characteristics associated with costs being mentioned in Randomized Controlled Trials.doi:10.1371/journal.pone.0012318.t002
Logistic regression analysis indicated that funding was the only factor associated with the inclusion of any actual cost (OR = 0.34, p = 0.009) or any mention of costs (OR = 0.63, p = 0.02). None of the other independent variables (conclusion, product age or primary author's country) were significantly associated with the inclusion of any actual cost or any mention of costs. The significant result of product age associated with the inclusion of any actual cost disappeared in regression analysis, suggesting that the inclusion of any actual costs with product age may be attributed to the correlation between product age and funding (i.e., industry funded RCTs would more likely to study novel drugs still on patent). The correlation coefficient between these two variables was high at 0.54, while no other two variables in the regression analysis had a correlation higher than 0.13.
Healthcare costs were mentioned in only 28% of RCTs of pharmaceutical therapy and actual drug costs were rarely (5%) included. The User's Guide to the Medical Literature  suggests that costs be considered in the application of all study results. Furthermore, most physicians believe that costs should be considered in clinical decision-making –. Unfortunately, physicians do not know the costs of drugs  or other healthcare interventions . Therefore, if clinicians were to consider costs in evaluating application of an RCT result, the drug cost would have to be included in the paper. It might be argued that physicians could access the costs elsewhere, although some authors have reported accurate costs are difficult to find , . The inclusion of costs, even a brief mention, would not be onerous and would help physicians consider and compare the relative benefit of a drug in relation to its' cost.
The total number of times costs were mentioned (166 times) appears to be relatively high, but this number is inflated by a few studies with cost as their primary focus. For example, a Lancet article includes costs 20 times which is equal to or more than all the articles from three of the other journals. We felt that these differences did not warrant statistical testing among the journals as the number of RCTs with any mention of cost did not differ among journals. Additionally, any differences between the total number of mentions could be due to chance since only 3% (6/188) of the RCTs provided 54% (90/166) of the total number of times costs were mentioned. Cost was a focus of these articles in contrast to the other 97% (182/188) of the RCTs.
Inclusion of healthcare costs did not vary by journal, primary author's country, study location, product age or conclusion. Although the inclusion of any actual cost was statistically less common in established (or older) drugs compared to novel (or newer), this finding disappeared on logistic regression. The association to product age and the inclusion of any actual cost was due to the correlation of funding and product age. Funding appears to be the only factor associated with the inclusion of cost information, as identified by the inclusion of any actual cost or any mention of cost in bi-variant analysis and multi-variant analysis of logistic regression. Industry funded studies were significantly less likely to mention costs than studies funded solely from non-profit sources. In fact, the likelihood that cost information was included in RCTs increased as the degree of industry funding declined. RCTs with any mention of costs increased across funding groups: from industry (18%) to mixed (31%) to non-profit (36%). This pattern was consistent with the inclusion of any actual costs: from industry (1%) to mixed (7%) to non-profit (15%) funding.
In light of previous studies showing that funding was associated with study conclusion –, , , it may be reasonable to conclude that funding could also be associated with the writing of the articles. It is possible that authors of industry-funded trials avoid discussion of costs because their products are usually more expensive. However, it is also possible that the authors of non-profit funded trials are more likely to include a discussion of costs because they feel obliged to consider costs as many non-profit sources (like government-linked sponsors) may be more cost-conscious.
A potential limitation of the study is the four-year delay from search to submission as cost reporting may have changed in that time. This is, however, highly unlikely as no incentive or initiative has been introduced to trigger such as change. Our journal selection may have impacted our results, particularly compared to journals with a health economic focus. Additionally, we included only RCTs — other types of articles may have included more cost information. That said, our goal was to examine clinically relevant RCTs in high impact clinical journals that are more often read and used by clinicians. As data extraction required some interpretation, particularly for the subjective areas such as study conclusion, there is the potential that different raters would categorize the conclusions differently. Our level of agreement was similar to investigators in previous studies assessing reporting in the literature. Our Kappa ranged from 0.87 to 0.74 while Pitkin et al  reported a 0.81 Kappa and Moher et al  report a Kappa values between 1 and 0.53.
Future research should examine other medical information resources, such as internet evidence-based summarized sites, other types of articles and perhaps other journals. If other resources provide cost information, the accuracy of the information should be examined, although defining true cost and accounting for cost difference over time and different locations will be challenging.
In summary, actual drug costs or any actual costs are rarely included in RCTs and costs are not mentioned at all in 72% of RCTs. Trials funded from non-profit sources were more likely to include cost information compared to trials with solely industry based funding. No other factors were associated with cost inclusion. More work is needed to provide physicians with the cost information that can inform their decision-making and potentially reduce healthcare costs.
Data Abstraction Form
(0.06 MB DOC)
(0.11 MB DOC)
GMA conceived of the study, acquired funding, and drafted the original manuscript. All authors but VM and BV worked on project development and study design. KL and GMA extracted cost data while CK and GMA extracted study characteristics. VM also reviewed data to confirm accuracy. GMA, KL and VM compiled the data and generated summary statistics. BV and DK assisted in statistical analysis. All authors participated in manuscript composition and give final approval of the article. GMA is the guarantor.
- 1. OECD Health Division (2006) OECD Health Data 2006, October 06. http://www.oecd.org/dataoecd/20/51/37622205.xls Accessed March 3, 2007.
- 2. Garrison L, Towse A (2003) The drug budget silo mentality in Europe: An overview. Value Health 6: S1–S9.
- 3. Seay M, Varma P (2005) Pharmaceuticals: pharmaceutical cost controls--2005. End of Year Issue Brief. Issue Brief Health Policy Track Serv 31: 1–20.
- 4. Goldman DP, Joyce GF, Escarce JJ, Pace JE, Solomon MD, et al. (2004) Pharmacy benefits and the use of drugs by the chronically ill. JAMA 291: 2344–2350.
- 5. Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, et al. (2001) Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 285: 421–429.
- 6. Lexchin J, Grootendorst P (2004) Effects of prescription drug users fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence. Int J Health Serv 34: 101–122.
- 7. Anis AH, Guh DP, Lacaille D, Marra CA, Rashidi AA, et al. (2005) When patients have to pay a share of drug costs: effects on frequency of physician visits, hospital admissions and filling of prescriptions. CMAJ 173: 1335–1339.
- 8. Hsu J, Price M, Huang J, Brand R, Fung V, et al. (2006) Unintended consequences of caps on medicare drug benefits. N Eng J Med 354: 2349–2359.
- 9. Bovier PA, Martin DP, Perneger TV (2005) Cost-consciousness among Swiss physicians: cross-sectional survey. BMC Health Serv Res 5:72. Available: http://www.biomedcentral.com/1472-6963/5/72. Accessed 26 February 2007.
- 10. Prosser H, Walley T (2005) A qualitative study of GP's and PCO stakeholders' views on the importance and influence of cost on prescribing. Soc Sci Med 60: 1335–1346.
- 11. Shrank WH, Joseph GJ, Choudhry NK, Young HN, Ettner SL, et al. (2005) Physicians' perceptions of relevant prescription drug costs: Do costs the individual patient or to the population matter most? Am J Manag Care 12: 545–551.
- 12. Salman H, Bergman M, Hart J, Neuman V, Zevin D, et al. (1999) The effect of drug cost on hypertension treatment decision. Public Health 113: 243–246.
- 13. Hart J, Salman H, Bergman M, Neuman V, Rudniki C, et al. (1997) Do drug costs affect physicians' prescription decisions? J Intern Med 241: 415–420.
- 14. Hux JE, Naylor DC (1994) Drug prices and Third Party Payment, do they influence medication selection. Pharmacoeconomics 5: 343–350.
- 15. Beilby JJ, Silagy CA (1997) Trials of Providing Costing information to GP's. Med J Aust 167: 89–92.
- 16. Roth EJ, Plastaras CT, Mullin MS, Fillmore J, Moses ML (2001) A simple institutional educational intervention to decrease use of selected expensive medications. Arch Phys Med Rehabil 82: 633–636.
- 17. Guterman JJ, Chernof BA, Mares B, Gross-Schulman SG, Gan PG, et al. (2002) Modifying provider behavior: a low-tech approach to pharmaceutical ordering. J Gen Intern Med 17: 792–796.
- 18. Allan GM, Lexchin J, Wiebe N (2007) Physician awareness of drug cost: A systematic review. PLOS Med 4(9): e283. doi:10.1371/journal.pmed.0040283.
- 19. Innes G, Grafstein E, McGrogan J (2000) Do emergency physicians know the costs of medical care? CJEM 2: 95–102.
- 20. Ringenberg R (1998) Cost awareness by family practice residents of commonly used laboratory tests, X-ray tests and medications. Indiana Med 81: 136–141.
- 21. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535. doi:10.1136/bmj.b2535.
- 22. Bhandari M, Busse JW, Jackowski D, Montori VM, Schünemann H, et al. (2004) Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 170(4): 477–80.
- 23. Yaphe J, Edman R, Knishkowy B, Herman J (2001) The association between funding by commercial interests and study outcome in randomized controlled drug trials. Fam Pract 18: 565–568.
- 24. Kjaergard LL, Als-Nielsen B (2002) Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in BMJ. BMJ 325: 249–252.
- 25. Pitkin RM, Branagan MA, Burmeister LF (1999) Accuracy of Data in Abstracts of Published Research Articles. JAMA 281: 1110–11.
- 26. Moher D, Jones A, Lepage L (2001) Use of the CONSORT Statement and Quality of Reports of Randomized Trials. JAMA 285: 1992–95.
- 27. Guyatt G, Rennie D, Meade MO, Cook DJ (2008) Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 2nd Edition. McGraw-Hill Companies, Inc.
- 28. Allan GM, Lexchin J (2008) Physician Awareness of Diagnostic and Non-drug Therapeutic Costs: A Systematic Review. Int J Technol Assess Health Care 24: 158–65.
- 29. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL (2003) Association of funding and conclusions in randomized drug trials. JAMA 2003; 290: 921–28.
- 30. Lexchin J, Bero LA, Djulbegovic B, Clark O (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326: 1167–70.